## UHS: Universal Health Services, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.7% below STRENGTH zone (3.0-6.0%); PEG 1.87 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($210.76)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 5
- **Sentiment:** Neutral (Bullish: 1, Bearish: 0)

**1. Globeflex Capital L P Acquires 5,977 Shares of Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251213T050827 | Somewhat-Bullish | Relevance: 100%
- Globeflex Capital L P increased its stake in Universal Health Services (NYSE:UHS) by 15.5%, acquiring 5,977 additional shares to bring its total holding to 44,538 shares valued at approximately $8.07 million. Institutional investors collectively own about 86.05% of the company, which recently reported strong quarterly earnings and announced a dividend. Analysts have a mixed view on UHS, with a consensus "Hold" rating and an average price target of $234.14.

**2. Natixis Buys 4,846 Shares of Universal Health Services, Inc. $UHS**
- Source: MarketBeat | 20251212T150853 | Bullish | Relevance: 100%
- Natixis significantly increased its stake in Universal Health Services (NYSE:UHS) by 102.3% in Q2, acquiring an additional 4,846 shares to hold a total of 9,585 shares valued at $1.736 million. This strong institutional interest comes as Universal Health Services exceeded Q3 earnings expectations with $5.69 EPS and $4.50 billion in revenue, and declared a $0.20 quarterly dividend. Despite notable insider stock sales, analyst consensus remains a "Hold" with a target price of $234.14, reflecting continued confidence in the company's performance.

**3. HCA, Tenet, UHS receive FTC letters over noncompete agreements**
- Source: Modern Healthcare | 20251210T050000 | Somewhat-Bearish | Relevance: 71%
- HCA, Tenet, and UHS have received letters from the Federal Trade Commission (FTC) regarding their noncompete agreements. This indicates scrutiny from the FTC over such practices within the healthcare industry. The article by Alex Kacik highlights this development in regulatory oversight.

**4. HCA, Tenet, UHS receive FTC letters over noncompete agreements**
- Source: Modern Healthcare | 20251210T110555 | Somewhat-Bearish | Relevance: 71%
- Three major healthcare providers, HCA, Tenet, and UHS, have received letters from the Federal Trade Commission (FTC) regarding their use of noncompete agreements. This action highlights the ongoing scrutiny of such agreements in the healthcare industry and their potential impact on competition and employee mobility. The article also touches upon other healthcare-related news, including new GOP health bills and insurance concerns.

**5. Universal Health Realty (NYSE: UHT) lifts payout by $0.005 to $0.745 per share**
- Source: Stock Titan | 20251210T210938 | Neutral | Relevance: 62%
- Universal Health Realty Income Trust (NYSE: UHT) announced that its Board of Trustees voted to increase the quarterly dividend by $0.005, raising it to $0.745 per share. The dividend will be paid on December 31, 2025, to shareholders of record as of December 22, 2025. Universal Health Realty Income Trust is a real estate investment trust specializing in healthcare and human service facilities, with 76 investments across 21 states.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Guggenheim | $274 | $253 | +8% |
| 2025-11-13 | Wells Fargo | $259 | $249 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Guggenheim | main | Buy |
| 2025-11-13 | Wells Fargo | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($11.07M) |
| Sells | 3 ($30.51M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 50.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (-3.4%)
- First Eagle Investme: 8.4% (+0.0%)
- Blackrock Inc.: 8.0% (-11.9%)
- State Street Corpora: 4.7% (-3.1%)
- FMR, LLC: 3.8% (+0.1%)

### Key Risks

1. Heavy insider selling: $31M sold (3 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.87 elevated, pricing in significant growth expectations. Analyst sentiment positive (2 raises, avg +6%). Insider selling cluster ($30.5M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $14.2B |
| Beta | 1.27 |
| 52W Range | $152.33 - $246.33 |
| Short Interest | 4.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.87 |
| Forward P/E | 9.4 |
| Current P/E | 10.2 |
| YoY Growth | 8.3% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -5.3% to -1.7% (+3.6% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.7pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.6%) - potential reversal signal. Long-term uptrend intact (above SMA200 at 1.17x) but short-term weakness (below SMA20). MACD histogram bearish (-2.47), momentum weakening. RSI neutral at 44. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.67% (CS: 13) | Neutral |
| RSI_14 | 43.7 | Neutral |
| MACD Histogram | -2.47 | Bearish |
| vs SMA20 | 0.962x | Below |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.170x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $222.60
- **Stop Loss:** $210.76 (5.3% risk)
- **Target:** $234.44 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 84
- **Position Value:** $18,698.40
- **Portfolio %:** 18.70%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-25 (Est: $5.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.95 | $5.69 | +14.9% |
| 2025Q2 | $4.96 | $5.35 | +8.0% |
| 2025Q1 | $4.36 | $4.84 | +11.1% |
| 2024Q4 | $4.18 | $4.92 | +17.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*